GET DAILY SIGNALSCorbus Pharmaceuticals (CRBP): Analyst Targets Point to +890% Upside – What Would It Take?
Key Takeaways
- The central target used here is $35, the arithmetic mean of nine recent analyst price targets that I verified individually, rounded from a calculated average of roughly $35.22.
- The latest verified closing price is about $3.52, meaning the target implies an upside of roughly 890%—an unusually large move that reflects how far the shares have fallen.
- The verified analyst range is wide, from a low of $24 (Mizuho) to a high of $48 (Oppenheimer), signaling genuine disagreement about the company's clinical-stage pipeline.
- Support comes from the oncology and obesity pipeline—led by CRB-701 and CRB-913—plus a cash balance of about $115 million, which management says funds operations into 2028.
- The biggest risks are steep cash burn, a third-quarter loss that missed estimates, repeated analyst target cuts, and the gap between the current price and even the lowest Wall Street target.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage biotechnology company developing therapies for cancer and obesity. Because the company has no approved products and minimal revenue, analysts value it almost entirely on pipeline potential, which is why their targets vary so widely.
I reviewed nine individually attributable, recent price targets. They span from $24 (Mizuho, October 2026) and $28 (B. Riley) at the conservative end, through $30 (Wedbush), $33 (Jefferies), $35 (H.C. Wainwright), $36 (RBC Capital), and $38 (LifeSci Capital), up to $45 (Guggenheim) and $48 (Oppenheimer). The arithmetic mean of these nine targets is about $35.22, which I round to a clean $35 central target. Notably, several firms have been cutting targets as the stock has fallen: Oppenheimer trimmed $52 to $48, Wedbush cut $38 to $30, and Mizuho lowered $33 to $24. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
These are published analyst expectations, not an official consensus, and they are not a guarantee. The unusually wide range reflects genuine disagreement about whether CRB-701 and CRB-913 can deliver commercially meaningful data.
Current Market Position and Path Toward the Target
The latest verified close for CRBP is about $3.52, giving the company a market capitalization of roughly $68 million. Reaching a $35 target would require a gain of approximately 890%—by any standard, a very large move. The shares have fallen about 75% over the past year, and even the lowest analyst target of $24 sits far above the current price, which is itself a warning sign that targets may not yet reflect the stock's repricing.
In its third quarter, Corbus reported a net loss of about $37.8 million, or $1.81 per share, missing consensus estimates, with no reported revenue. The company ended September with roughly $115 million in cash, cash equivalents, and investments, which it says supports operations into 2028. A path toward the target would require clinical milestones—notably CRB-701 data—to re-rate the shares substantially.
What Could Support a Move Toward the Target
The bull case rests on the pipeline. CRB-701, a Nectin-4-targeting antibody-drug conjugate, has entered the TEMPO-1 registrational study in second-line oropharyngeal cancer, with the first patient dosed in September 2026. Combination data with Keytruda in first-line oropharyngeal cancer are expected in early 2027. Separately, CRB-913, a peripherally restricted CB1 inverse agonist for obesity, showed roughly 5% placebo-adjusted weight loss at 12 weeks in the CANYON-1 study—efficacy comparable to some oral GLP-1 treatments, with a favorable safety profile. Positive data, a partnership, or an accelerated approval path could meaningfully change sentiment for a stock now valued near its cash.
What Could Prevent the Target From Being Reached
The risks are substantial. The company is burning cash with no product revenue, and losses widened in the third quarter. Repeated downward target revisions suggest analysts are recalibrating expectations. Insiders, including the CEO and CFO, have been net sellers, and short interest is elevated at roughly 18% of float. A clinical setback, disappointing CRB-701 or CRB-913 data, a dilutive financing, or simply continued valuation compression could keep the shares far below $35, or push them lower.
Technical Levels and Market Structure
The stock trades near its 52-week low of roughly $3.73, which now acts as a key support level. It sits well below its 50-day and 200-day moving averages, which have been trending lower—a bearish long-term structure. The nearest meaningful resistance zone is the prior consolidation area around $4.50 to $5.50, with the psychological $5 and $10 levels farther above. Until the shares reclaim those averages, the technical picture offers little confirmation of a trend change.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though biotech targets are especially sensitive to binary clinical events. Investors should monitor the CRB-701 combination data expected in early 2027, enrollment progress in TEMPO-1, further CRB-913 obesity data, quarterly cash burn, and any financing or partnership announcements, as well as ongoing analyst target revisions and earnings updates.
Using AI Daily Buy/Sell Signals for Monitoring
In my view, AI Daily Buy/Sell Signals from Tickeron have become a useful part of my routine for names like this. The platform applies artificial intelligence to scan thousands of stocks and ETFs, flagging Buy, Sell, or Hold ideas based on technical shifts and market conditions. For a volatile, heavily shorted stock such as CRBP, these signals help me stay on top of momentum changes without relying solely on manual chart work. I find it efficient when cross-checking analyst views with real-time data.
Final Assessment
Can CRBP reach $35? The central target is the average of nine analyst price targets, spanning $24 to $48—and it sits roughly 890% above the current price of about $3.52. Reaching it would require not just positive clinical data but a near-total repricing of a clinical-stage company with no product revenue and widening losses. The pipeline offers real optionality, and the cash runway into 2028 removes immediate insolvency risk, but the wide analyst range, repeated target cuts, and negative technical structure all argue for caution. The honest answer is that the target is achievable only if the company's clinical catalysts succeed on a scale that reverses a year-long decline—a high bar that should be monitored, not assumed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
CRBP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CRBP turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRBP's RSI Oscillator exited the oversold zone, 38 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +23.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 227 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRBP entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.498). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of drug development services
Industry Biotechnology
Advertisement